These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32670862)
1. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma. Shi W; Zhang S; Ma D; Yan D; Zhang G; Cao Y; Wang Z; Wu J; Jiang C Front Oncol; 2020; 10():694. PubMed ID: 32670862 [No Abstract] [Full Text] [Related]
2. SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway. Shi W; Ma D; Cao Y; Hu L; Liu S; Yan D; Zhang S; Zhang G; Wang Z; Wu J; Jiang C Front Mol Biosci; 2021; 8():598218. PubMed ID: 33968977 [TBL] [Abstract][Full Text] [Related]
3. Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition. Janakiraman H; Gao Z; Zhu Y; Dong J; Becker SA; Janneh A; Ogretmen B; Camp ER World J Oncol; 2024 Oct; 15(5):744-757. PubMed ID: 39328328 [TBL] [Abstract][Full Text] [Related]
4. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. Zhou J; Chen J; Yu H Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730 [TBL] [Abstract][Full Text] [Related]
5. The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth. Xu L; Jin L; Yang B; Wang L; Xia Z; Zhang Q; Xu J Oncotarget; 2018 Jan; 9(2):2384-2394. PubMed ID: 29416779 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor. Guan S; Liu YY; Yan T; Zhou J Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045 [TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050 [TBL] [Abstract][Full Text] [Related]
8. CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma. Ma D; Liu S; Liu K; He Q; Hu L; Shi W; Cao Y; Zhang G; Xin Q; Wang Z; Wu J; Jiang C Transl Oncol; 2024 Sep; 47():102040. PubMed ID: 38954975 [TBL] [Abstract][Full Text] [Related]
9. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639 [TBL] [Abstract][Full Text] [Related]
10. Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. Baker DA; Eudaly J; Smith CD; Obeid LM; Gilkeson GS Rheumatol Int; 2013 Oct; 33(10):2677-81. PubMed ID: 23011090 [TBL] [Abstract][Full Text] [Related]
11. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959 [TBL] [Abstract][Full Text] [Related]
12. A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC. Yang H; Chen D; Wu Y; Zhou H; Diao W; Liu G; Li Q Cancer Metab; 2023 Dec; 11(1):27. PubMed ID: 38111012 [TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase 2 and p62 regulation are determinants of sexual dimorphism in hepatocellular carcinoma. Green CD; Brown RDR; Uranbileg B; Weigel C; Saha S; Kurano M; Yatomi Y; Spiegel S Mol Metab; 2024 Aug; 86():101971. PubMed ID: 38925249 [TBL] [Abstract][Full Text] [Related]
14. Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson's disease and in MPP+ -treated MN9D cells in vitro. Sivasubramanian M; Kanagaraj N; Dheen ST; Tay SS Neuroscience; 2015 Apr; 290():636-48. PubMed ID: 25637806 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413 [TBL] [Abstract][Full Text] [Related]
16. Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. Ding X; Zhang Y; Huang T; Xu G; Peng C; Chen G; Kong B; Friess H; Shen S; Lv Y; Roberts LR; Wang L; Zou X Am J Cancer Res; 2019; 9(3):546-561. PubMed ID: 30949409 [TBL] [Abstract][Full Text] [Related]
17. TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib. Wang Z; Zhu Q; Li X; Ren X; Li J; Zhang Y; Zeng S; Xu L; Dong X; Zhai B Am J Cancer Res; 2022; 12(9):4343-4360. PubMed ID: 36225636 [TBL] [Abstract][Full Text] [Related]
18. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice. Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278 [TBL] [Abstract][Full Text] [Related]
19. Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Karabicici M; Azbazdar Y; Ozhan G; Senturk S; Firtina Karagonlar Z; Erdal E Front Cell Dev Biol; 2021; 9():639779. PubMed ID: 34458250 [TBL] [Abstract][Full Text] [Related]
20. The Role of Sphingomyelin Metabolism in the Protection of Rat Brain Microvascular Endothelial Cells by Mild Hypothermia. Zhang HH; Wang L; Zhang W; Wan Z Neurocrit Care; 2022 Apr; 36(2):546-559. PubMed ID: 34508278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]